Ultragenyx Pharmaceutical(RARE) - 2023 Q4 - Earnings Call Transcript

I heard the extension cohort. You're asking from the ones we presented how long they go out. The -- by the time we get to end of Phase II, we'll have patients who have had two years of treatment probably, but it will be somewhere between a year to two years of treatment of exposure for all those patients. Emil Kakkis Operator I have two quick ones. The first of all, as the commercial products, namely Dojolvi and Crysvita. I know there's some seasonality in the fourth quarter numbers. But when you analyze ou ...